GTCR to acquire generic drug maker Zentiva

Core Insights - Zentiva, a Czech producer of generic medications, is set for a change in ownership as Advent has agreed to sell the company to GTCR for an estimated €4.1 billion ($4.8 billion) [1] - Zentiva operates in over 30 countries, focusing on the development, production, and distribution of medicines [1][2] Company Overview - Zentiva has four wholly-owned manufacturing facilities and a network of external production partners, ensuring a consistent supply of medications [2] - The company employs more than 5,000 people and has experienced significant growth since Advent's acquisition from Sanofi in 2018 [2] Growth and Transformation - Advent's collaboration with Zentiva's management has been crucial for expanding the product range and manufacturing capabilities, both organically and through strategic acquisitions [3] - Zentiva is positioned as a self-reliant entity with a strong emphasis on research and development [3] Leadership Statements - CEO Steffen Saltofte highlighted Advent's role in Zentiva's transformation, emphasizing their investment in capabilities and manufacturing [4] - GTCR's managing director Sean Cunningham expressed enthusiasm about partnering with Zentiva's management for its next growth phase, noting the company's strong track record and efficient manufacturing platform [6] Transaction Details - The acquisition is subject to regulatory approvals and is expected to be finalized in early 2026 [4] - Advent was supported by Goldman Sachs and PJT Partners as financial advisors, while GTCR's advisory team included Barclays Bank, BNP Paribas, and Morgan Stanley [5]